Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is cup and handle chart.
From $6.18-$3.095 = $ 3.09
The run started from $5.54, + $3.09 = $8.63. Short term target. Probably will see it in Sept. before option expiration date. Then might close at $8 on OE.
If receive FDA approval in October/November, $12-$15 will be seen quickly.
I think you're right on the money. The FDA has a great deal of knowledge about MIRV, the Soraya trial was based on the guidance the FDA provided and it met the goals they established. Even a September approval is possible, though unlikely.
I believe the $8 target you set could be hit by mid-September, I believe that double digits will be seen post approval, and perhaps shortly before it.
Gary
That's what this buying is about?
I believe FDA approval will come in October, so the run will start very soon. And it is quite bullish chart now, short term target $8.
Any thoughts on whether the FDA will act significantly before the November 28 PDUFA date. I believe it's very possible in that the Soraya trial was one developed by IMGN in collaboration with the FDA and they've met the goals established then.
Frankly the FDA had seen these benefits proven in a subset of their earlier trial, they could have granted an approval years ago but they wanted more proof. Now they have it, why not make the decision to accept it early.
Gary
Agreed there vim.
I am back in after be in and out a couple times. The previous time I re-entered was after the RTF mess of TDM-1. And same then, they had plenty for cash to wait for the next trial to read and garner approval.
Decent shots on goal today w/o risk of dilution.
Here's the release of IMGN's presentation at ASCO.
https://ih.advfn.com/stock-market/NASDAQ/immunogen-IMGN/stock-news/88225248/immunogen-presents-additional-efficacy-and-safety
Gary
I give up trying to figure out the stock market
We’re all simply the dog’s tail
GLTA
Can anyone believe that we're down on the day we learn the PDUFA date for our drug. Some were trying to create doubt that the FDA would accept the BLA, that doubt is eliminated and while approval is never certain, the FDA is already quite familiar with the drug and I believe Soraya met the criteria the FDA required. I like the chances and believe that if it's to be approved they may do so well prior to the 28 November date.
I don't know what will be presented at ASCO, but if it doesn't spur the share price I would hope that the company holds a Science Day, it's something they've done in the past and I really think they need to get their message out on all that's happening here. This is not a one trick pony.
Gary
The damn may well have busted!
“The clinical-stage biotech, ImmunoGen (NASDAQ:IMGN) announced on Monday that the US Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for its ovarian cancer therapy mirvetuximab soravtansine under priority review.”
Hopefully the announcement of a PDUFA date and presentation at ASCO will rally the stock, I believe we could get the date established at any time.
Gary
IMGN getting kicked around like a soccer ball...
It's a rigged market...
New S-A article on IMGN
https://seekingalpha.com/article/4500665-immunogen-way-beyond-soraya?mailingid=27320497&messageid=2800&serial=27320497.1831&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=27320497.1831
I believe it's pretty much on the money, if we're right, it won't be that long before we're in the money.
Gary
Yep hes got it rt
As best I can figure it is a combination of the RBC downgrade and the PFS numbers on the patients with prior bevacizumab exposure.
The confirmatory MIRASOL trial has PFS as the primary. In SORAYA the PFS was OK, but better in bev naive patients.
The concern is that the SORAYA trial might have had less bev patients because it required a PARP inhibitor but the confirmatory MIRASOL trial does not require PARPs, so could have more bev exposure.
I do not know how real the concern is. Alas I only have the dumbed down video and PRs to base it on. Hopefully somebody can get the full presentation soon.
I say dilution
Here's a video about the presentation made yesterday that's had a corporate presentation this morning:
Historic short interest:
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover
02/15/2022 12,964,688 1.29 2,925,151 4.43
01/31/2022 12,799,470 (2.35) 2,650,496 4.83
01/14/2022 13,107,052 0.64 2,300,759 5.70
12/31/2021 13,023,792 25.75 2,727,064 4.78
12/15/2021 10,356,523 22.01 8,255,872 1.25
11/30/2021 8,487,963 (18.60) 7,564,223 1.12
11/15/2021 10,427,311 (35.64) 2,009,966 5.19
10/29/2021 16,200,572 (7.02) 1,365,145 11.87
10/15/2021 17,422,883 (9.53) 1,301,102 13.39
09/30/2021 19,257,389 (8.85) 1,409,260 13.66
09/15/2021 21,126,244 (1.17) 1,400,971 15.08
08/31/2021 21,376,665 5.16 1,315,999 16.24
08/13/2021 20,328,359 (2.06) 1,328,755 15.30
07/30/2021 20,756,005 2.41 1,151,391 18.03
07/15/2021 20,267,352 (8.35) 1,466,584 13.82
06/30/2021 22,113,431 (4.13) 1,754,787 12.60
06/15/2021 23,065,947 11.24 2,328,437 9.91
05/28/2021 20,741,899 (0.54) 2,792,211 7.43
05/14/2021 20,854,878 (0.20) 1,337,813 15.59
04/30/2021 20,895,982 0.29 1,285,776 16.25
04/15/2021 20,835,484 (6.78) 1,514,333 13.76
03/31/2021 22,350,365 0.16 1,858,450 12.03
03/15/2021 22,314,403 (2.53) 1,840,394 12.12
02/26/2021 22,893,009 (14.03) 3,433,013 6.67
02/12/2021 26,628,801 (1.28) 1,515,596 17.57
01/29/2021 26,974,172 3.22 2,068,358 13.04
01/15/2021 26,132,538 (4.05) 2,237,983 11.68
12/31/2020 27,235,886 19.50 2,558,178 10.65
12/15/2020 22,791,117 10.71 2,460,173 9.26
11/30/2020 20,586,156 (3.02) 1,910,474 10.78
11/13/2020 21,228,310 13.42 2,399,751 8.85
10/30/2020 18,715,978 16.67 2,736,373 6.84
10/15/2020 16,041,652 (7.49) 4,202,811 3.82
09/30/2020 17,341,107 10.43 2,035,668 8.52
09/15/2020 15,703,514 (10.13) 2,253,070 6.97
08/31/2020 17,472,965 (0.99) 1,815,645 9.62
08/14/2020 17,648,430 (0.70) 1,634,948 10.79
07/31/2020 17,772,471 9.71 1,996,745 8.90
07/15/2020 16,199,537 (1.69) 2,202,313 7.36
06/30/2020 16,477,343 38.20 2,029,157 8.12
06/15/2020 11,923,174 (1.24) 2,232,855 5.34
05/29/2020 12,072,735 (5.79) 2,311,699 5.22
05/15/2020 12,814,765 5.74 2,296,874 5.58
04/30/2020 12,119,128 (6.70) 2,539,686 4.77
04/15/2020 12,989,019 (23.57) 2,288,671 5.68
03/31/2020 16,994,857 4.66 3,326,321 5.11
03/13/2020 16,237,859 61.75 2,383,175 6.81
02/28/2020 10,038,565 4.46 4,489,696 2.24
02/14/2020 9,609,709 (5.79) 2,130,443 4.51
01/31/2020 10,200,828 13.09 3,121,831 3.27
01/15/2020 9,019,983 (28.16) 1,972,819 4.57
12/31/2019 12,554,793 14.29 5,207,061 2.41
12/13/2019 10,985,037 29.30 2,208,991 4.97
11/29/2019 8,495,994 8.56 1,784,206 4.76
11/15/2019 7,826,143 8.95 2,026,284 3.86
10/31/2019 7,183,276 0.53 1,146,750 6.26
10/15/2019 7,145,499 4.52 1,269,342 5.63
09/30/2019 6,836,271 40.97 2,502,661 2.73
09/13/2019 4,849,495 0.14 1,401,871 3.46
08/30/2019 4,842,909 (3.46) 1,169,467 4.14
08/15/2019 5,016,602 (6.51) 2,470,784 2.03
07/31/2019 5,365,890 (22.42) 2,235,313 2.40
Billionaire investor has IMGN as a top pick.
https://finance.yahoo.com/news/billionaire-ken-griffin-snaps-3-001412023.html
I believe we'll see much higher prices later this year as more is revealed on trial, and drugs advance to approval.
Gary
Yep Gary this will go above 20 this year on pos data is my guess
IMGN gets an outperform rating, and $18 target.
https://thefly.com/landingPageNews.php?id=3457364&headline=IMGN-ImmunoGen-initiated-with-an-Outperform-at-BMO-Capital
In the Annual Report later this month I'd not be surprised to have them announce the filing of the BLA. A partnership before the end of the year might very well bring well above the $18 target.
Gary
The presentation at JP Morgan was viewed positively, yet we're down substantially since then. I don't know who's behind it, but believe the stock is being manipulated and apparently will continue to be until something so positive occurs that demand for the stock sends us to prices not seen in years, perhaps even prices that have never seen before.
Gary
Historic short interest:
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover
12/31/2021 13,023,792 25.75 2,727,064 4.78
12/15/2021 10,356,523 22.01 8,255,872 1.25
11/30/2021 8,487,963 (18.60) 7,564,223 1.12
11/15/2021 10,427,311 (35.64) 2,009,966 5.19
10/29/2021 16,200,572 (7.02) 1,365,145 11.87
10/15/2021 17,422,883 (9.53) 1,301,102 13.39
09/30/2021 19,257,389 (8.85) 1,409,260 13.66
09/15/2021 21,126,244 (1.17) 1,400,971 15.08
08/31/2021 21,376,665 5.16 1,315,999 16.24
08/13/2021 20,328,359 (2.06) 1,328,755 15.30
07/30/2021 20,756,005 2.41 1,151,391 18.03
07/15/2021 20,267,352 (8.35) 1,466,584 13.82
06/30/2021 22,113,431 (4.13) 1,754,787 12.60
06/15/2021 23,065,947 11.24 2,328,437 9.91
05/28/2021 20,741,899 (0.54) 2,792,211 7.43
05/14/2021 20,854,878 (0.20) 1,337,813 15.59
04/30/2021 20,895,982 0.29 1,285,776 16.25
04/15/2021 20,835,484 (6.78) 1,514,333 13.76
03/31/2021 22,350,365 0.16 1,858,450 12.03
03/15/2021 22,314,403 (2.53) 1,840,394 12.12
02/26/2021 22,893,009 (14.03) 3,433,013 6.67
02/12/2021 26,628,801 (1.28) 1,515,596 17.57
01/29/2021 26,974,172 3.22 2,068,358 13.04
01/15/2021 26,132,538 (4.05) 2,237,983 11.68
12/31/2020 27,235,886 19.50 2,558,178 10.65
12/15/2020 22,791,117 10.71 2,460,173 9.26
11/30/2020 20,586,156 (3.02) 1,910,474 10.78
11/13/2020 21,228,310 13.42 2,399,751 8.85
10/30/2020 18,715,978 16.67 2,736,373 6.84
10/15/2020 16,041,652 (7.49) 4,202,811 3.82
09/30/2020 17,341,107 10.43 2,035,668 8.52
09/15/2020 15,703,514 (10.13) 2,253,070 6.97
08/31/2020 17,472,965 (0.99) 1,815,645 9.62
08/14/2020 17,648,430 (0.70) 1,634,948 10.79
07/31/2020 17,772,471 9.71 1,996,745 8.90
07/15/2020 16,199,537 (1.69) 2,202,313 7.36
06/30/2020 16,477,343 38.20 2,029,157 8.12
06/15/2020 11,923,174 (1.24) 2,232,855 5.34
05/29/2020 12,072,735 (5.79) 2,311,699 5.22
05/15/2020 12,814,765 5.74 2,296,874 5.58
04/30/2020 12,119,128 (6.70) 2,539,686 4.77
04/15/2020 12,989,019 (23.57) 2,288,671 5.68
03/31/2020 16,994,857 4.66 3,326,321 5.11
03/13/2020 16,237,859 61.75 2,383,175 6.81
02/28/2020 10,038,565 4.46 4,489,696 2.24
02/14/2020 9,609,709 (5.79) 2,130,443 4.51
01/31/2020 10,200,828 13.09 3,121,831 3.27
01/15/2020 9,019,983 (28.16) 1,972,819 4.57
12/31/2019 12,554,793 14.29 5,207,061 2.41
12/13/2019 10,985,037 29.30 2,208,991 4.97
11/29/2019 8,495,994 8.56 1,784,206 4.76
11/15/2019 7,826,143 8.95 2,026,284 3.86
10/31/2019 7,183,276 0.53 1,146,750 6.26
10/15/2019 7,145,499 4.52 1,269,342 5.63
09/30/2019 6,836,271 40.97 2,502,661 2.73
09/13/2019 4,849,495 0.14 1,401,871 3.46
08/30/2019 4,842,909 (3.46) 1,169,467 4.14
08/15/2019 5,016,602 (6.51) 2,470,784 2.03
07/31/2019 5,365,890 (22.42) 2,235,313 2.40
Here's a great summary report on IMGN for 2022.
https://msmoneymoves.com/2022/01/09/immunogen-enters-a-pivotal-year-in-2022/
I believe the biggest unknown involves ROW partnerships, I just hope that IMGN sticks to it's guns regarding keeping at least the U.S. for itself.
Let's see what they have to say at J.P. Morgan on Wednesday.
Gary
see you at 20 plus soon enough!
yep I read that too.
It's $26 billion now, it's been substantially higher a matter of months ago. Some time ago the market caps were nearly equal. In time that should happen again.
Gary
May I know what was SGEN market cap?
Motley Fool named IMGN #1 of 3 stocks flying under the radar going into 2022.
https://www.fool.com/investing/2021/12/11/3-under-the-radar-biotech-stocks-to-buy-in-2022/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
I believe we should get a boost out of ASH going into the New Year's. I believe the Motley Fool's estimate of up 50% next year will prove to be low after approval is gained. Frankly IMGN's market cap should be no less than a quarter that of SGEN, and it probably should be higher than that post approval.
Gary
Profitability
Profit Margin -55.41%
Operating Margin (ttm) -42.33%
Management Effectiveness
Return on Assets (ttm) -12.40%
Return on Equity (ttm) -413.68%
Income Statement
Quarterly Revenue Growth (yoy) -49.40%
EBITDA -51.95M
Net Income Avi to Common (ttm) -70.74M
Diluted EPS (ttm) -0.3570
Balance Sheet
Total Cash (mrq) 245.76M
Total Cash Per Share (mrq) 1.21
Total Debt (mrq) 19.4M
Total Debt/Equity (mrq) 25.17
Current Ratio (mrq) 2.42
Book Value Per Share (mrq) 0.38
Cash Flow Statement
Operating Cash Flow (ttm) -115.01M
Levered Free Cash Flow (ttm) -8.53M
2022 Quarter 3 for next trial??? That's a whole lotta cash to spend and equity to raise. Another year for a maybe... Add over $400,000,000 to mc Book Value is $0.37
Historic short interest:
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover
11/15/2021 10,427,311 (35.64) 2,009,966 5.19
10/29/2021 16,200,572 (7.02) 1,365,145 11.87
10/15/2021 17,422,883 (9.53) 1,301,102 13.39
09/30/2021 19,257,389 (8.85) 1,409,260 13.66
09/15/2021 21,126,244 (1.17) 1,400,971 15.08
08/31/2021 21,376,665 5.16 1,315,999 16.24
08/13/2021 20,328,359 (2.06) 1,328,755 15.30
07/30/2021 20,756,005 2.41 1,151,391 18.03
07/15/2021 20,267,352 (8.35) 1,466,584 13.82
06/30/2021 22,113,431 (4.13) 1,754,787 12.60
06/15/2021 23,065,947 11.24 2,328,437 9.91
05/28/2021 20,741,899 (0.54) 2,792,211 7.43
05/14/2021 20,854,878 (0.20) 1,337,813 15.59
04/30/2021 20,895,982 0.29 1,285,776 16.25
04/15/2021 20,835,484 (6.78) 1,514,333 13.76
03/31/2021 22,350,365 0.16 1,858,450 12.03
03/15/2021 22,314,403 (2.53) 1,840,394 12.12
02/26/2021 22,893,009 (14.03) 3,433,013 6.67
02/12/2021 26,628,801 (1.28) 1,515,596 17.57
01/29/2021 26,974,172 3.22 2,068,358 13.04
01/15/2021 26,132,538 (4.05) 2,237,983 11.68
12/31/2020 27,235,886 19.50 2,558,178 10.65
12/15/2020 22,791,117 10.71 2,460,173 9.26
11/30/2020 20,586,156 (3.02) 1,910,474 10.78
11/13/2020 21,228,310 13.42 2,399,751 8.85
10/30/2020 18,715,978 16.67 2,736,373 6.84
10/15/2020 16,041,652 (7.49) 4,202,811 3.82
09/30/2020 17,341,107 10.43 2,035,668 8.52
09/15/2020 15,703,514 (10.13) 2,253,070 6.97
08/31/2020 17,472,965 (0.99) 1,815,645 9.62
08/14/2020 17,648,430 (0.70) 1,634,948 10.79
07/31/2020 17,772,471 9.71 1,996,745 8.90
07/15/2020 16,199,537 (1.69) 2,202,313 7.36
06/30/2020 16,477,343 38.20 2,029,157 8.12
06/15/2020 11,923,174 (1.24) 2,232,855 5.34
05/29/2020 12,072,735 (5.79) 2,311,699 5.22
05/15/2020 12,814,765 5.74 2,296,874 5.58
04/30/2020 12,119,128 (6.70) 2,539,686 4.77
04/15/2020 12,989,019 (23.57) 2,288,671 5.68
03/31/2020 16,994,857 4.66 3,326,321 5.11
03/13/2020 16,237,859 61.75 2,383,175 6.81
02/28/2020 10,038,565 4.46 4,489,696 2.24
02/14/2020 9,609,709 (5.79) 2,130,443 4.51
01/31/2020 10,200,828 13.09 3,121,831 3.27
01/15/2020 9,019,983 (28.16) 1,972,819 4.57
12/31/2019 12,554,793 14.29 5,207,061 2.41
12/13/2019 10,985,037 29.30 2,208,991 4.97
11/29/2019 8,495,994 8.56 1,784,206 4.76
11/15/2019 7,826,143 8.95 2,026,284 3.86
10/31/2019 7,183,276 0.53 1,146,750 6.26
10/15/2019 7,145,499 4.52 1,269,342 5.63
09/30/2019 6,836,271 40.97 2,502,661 2.73
09/13/2019 4,849,495 0.14 1,401,871 3.46
08/30/2019 4,842,909 (3.46) 1,169,467 4.14
08/15/2019 5,016,602 (6.51) 2,470,784 2.03
07/31/2019 5,365,890 (22.42) 2,235,313 2.40
Historic short interest:
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
10/29/2021 16,200,572 (7.02) 1,365,145 11.87
10/15/2021 17,422,883 (9.53) 1,301,102 13.39
09/30/2021 19,257,389 (8.85) 1,409,260 13.66
09/15/2021 21,126,244 (1.17) 1,400,971 15.08
08/31/2021 21,376,665 5.16 1,315,999 16.24
08/13/2021 20,328,359 (2.06) 1,328,755 15.30
07/30/2021 20,756,005 2.41 1,151,391 18.03
07/15/2021 20,267,352 (8.35) 1,466,584 13.82
06/30/2021 22,113,431 (4.13) 1,754,787 12.60
06/15/2021 23,065,947 11.24 2,328,437 9.91
05/28/2021 20,741,899 (0.54) 2,792,211 7.43
05/14/2021 20,854,878 (0.20) 1,337,813 15.59
04/30/2021 20,895,982 0.29 1,285,776 16.25
04/15/2021 20,835,484 (6.78) 1,514,333 13.76
03/31/2021 22,350,365 0.16 1,858,450 12.03
03/15/2021 22,314,403 (2.53) 1,840,394 12.12
02/26/2021 22,893,009 (14.03) 3,433,013 6.67
02/12/2021 26,628,801 (1.28) 1,515,596 17.57
01/29/2021 26,974,172 3.22 2,068,358 13.04
01/15/2021 26,132,538 (4.05) 2,237,983 11.68
12/31/2020 27,235,886 19.50 2,558,178 10.65
12/15/2020 22,791,117 10.71 2,460,173 9.26
11/30/2020 20,586,156 (3.02) 1,910,474 10.78
11/13/2020 21,228,310 13.42 2,399,751 8.85
10/30/2020 18,715,978 16.67 2,736,373 6.84
10/15/2020 16,041,652 (7.49) 4,202,811 3.82
09/30/2020 17,341,107 10.43 2,035,668 8.52
09/15/2020 15,703,514 (10.13) 2,253,070 6.97
08/31/2020 17,472,965 (0.99) 1,815,645 9.62
08/14/2020 17,648,430 (0.70) 1,634,948 10.79
07/31/2020 17,772,471 9.71 1,996,745 8.90
07/15/2020 16,199,537 (1.69) 2,202,313 7.36
06/30/2020 16,477,343 38.20 2,029,157 8.12
06/15/2020 11,923,174 (1.24) 2,232,855 5.34
05/29/2020 12,072,735 (5.79) 2,311,699 5.22
05/15/2020 12,814,765 5.74 2,296,874 5.58
04/30/2020 12,119,128 (6.70) 2,539,686 4.77
04/15/2020 12,989,019 (23.57) 2,288,671 5.68
03/31/2020 16,994,857 4.66 3,326,321 5.11
03/13/2020 16,237,859 61.75 2,383,175 6.81
02/28/2020 10,038,565 4.46 4,489,696 2.24
02/14/2020 9,609,709 (5.79) 2,130,443 4.51
01/31/2020 10,200,828 13.09 3,121,831 3.27
01/15/2020 9,019,983 (28.16) 1,972,819 4.57
12/31/2019 12,554,793 14.29 5,207,061 2.41
12/13/2019 10,985,037 29.30 2,208,991 4.97
11/29/2019 8,495,994 8.56 1,784,206 4.76
11/15/2019 7,826,143 8.95 2,026,284 3.86
10/31/2019 7,183,276 0.53 1,146,750 6.26
10/15/2019 7,145,499 4.52 1,269,342 5.63
09/30/2019 6,836,271 40.97 2,502,661 2.73
09/13/2019 4,849,495 0.14 1,401,871 3.46
08/30/2019 4,842,909 (3.46) 1,169,467 4.14
08/15/2019 5,016,602 (6.51) 2,470,784 2.03
07/31/2019 5,365,890 (22.42) 2,235,313 2.40
Nope - when institutional ownership gets high they do shakeouts like this to get rid of retail - it's a buying opportunity.
Looks like a fund selling and loose hands following in fear.
Followers
|
61
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1106
|
Created
|
02/12/02
|
Type
|
Free
|
Moderators |
http://www.immunogen.com/about-us
http://finance.yahoo.com/q/h?s=IMGN
Our mission is to be the leader in the application of monoclonal antibodies for the treatment of cancer. We aim to achieve this by exploiting our expertise and experience in the identification of potential biological targets for cancer treatments, the development and humanization of monoclonal antibodies, and the creation of potent cell-killing agents designed for delivery by antibodies. Our Targeted Antibody Payload(TAP) technology uses tumor-targeting antibodies to deliver a highly potent cell-killing agent specifically to cancer cells to kill these cells with minimal damage to healthy tissue.
We are committed to the highest standards of scientific excellence and integrity for the benefit of patients, the medical community, our partners, shareholders and employees.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |